Monthly
US$200
Billed every month
Sign in to subscribeErythromycin Lactobionate for Injection
Matched- Active ingredients (original)
- ERYTHROMYCIN LACTOBIONATE
- Dosage form (original)
- INJECTABLE
- Route (original)
- INJECTION
Read these limits
- US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
- The Orange Book lists holder-submitted patents and does not cover all related patents.
- “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
- This page contains no sales or market-size data and cannot establish development value.
- Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.
US-approved products
Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Earliest approvalApproved before 1982
ANDA applications9
RLD applicantHOSPIRA INC
Currently marketed products: 4 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| A062563-001 | ERYTHROMYCIN | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1985/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A062563-002 | ERYTHROMYCIN | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1985/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A062586-001 | ERYTHROCIN | ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1988/01/04 | N / N | DISCONTINUED | openFDA ↗ |
| A062586-002 | ERYTHROCIN | ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1988/01/04 | N / N | DISCONTINUED | openFDA ↗ |
| A062604-001 | ERYTHROMYCIN LACTOBIONATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1986/11/24 | N / N | DISCONTINUED | openFDA ↗ |
| A062604-002 | ERYTHROMYCIN LACTOBIONATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1986/11/24 | N / N | DISCONTINUED | openFDA ↗ |
| A062638-001 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1986/10/31 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A062638-002 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1986/10/31 | N / N | DISCONTINUED | openFDA ↗ |
| A062993-001 | ERYTHROMYCIN LACTOBIONATE | BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1989/05/09 | N / N | DISCONTINUED | openFDA ↗ |
| A062993-002 | ERYTHROMYCIN LACTOBIONATE | BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1989/05/09 | N / N | DISCONTINUED | openFDA ↗ |
| A063253-001 | ERYTHROMYCIN LACTOBIONATE | TEVA PARENTERAL MEDICINES INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1993/07/30 | N / N | DISCONTINUED | openFDA ↗ |
| A063253-002 | ERYTHROMYCIN LACTOBIONATE | TEVA PARENTERAL MEDICINES INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1993/07/30 | N / N | DISCONTINUED | openFDA ↗ |
| A211086-001 | ERYTHROMYCIN LACTOBIONATE | EXELA PHARMA SCIENCES LLC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 2020/09/17 | N / N | DISCONTINUED | openFDA ↗ |
| A215290-001 | ERYTHROMYCIN LACTOBIONATE | NEXUS PHARMACEUTICALS LLC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 2022/02/14 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A216761-001 | ERYTHROMYCIN LACTOBIONATE | GLAND PHARMA LTD | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 2024/11/19 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N050182-002 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| N050182-003 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| N050609-001 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 500MG BASE/VIAL | 1986/09/24 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N050609-002 | ERYTHROCIN | HOSPIRA INC | INJECTABLE | INJECTION | ERYTHROMYCIN LACTOBIONATE: EQ 1GM BASE/VIAL | 1986/09/24 | Y / N | DISCONTINUED | openFDA ↗ |
Listed US patents
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
Latest listed patent expiration—
Substance patent expiration (DS flag)—
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| Not listed | ||||||
Exclusivity source records
FDA exclusivity code list ↗Latest exclusivity expiration: —
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| Not listed | |||
Chinese record details
Chinese product landscape ↗The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Catalog holders 4
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Guangdong Yue He Ze Drug Research Co., Ltd. romanized | 国药准字H20265708See source | 2026/08/25 | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265577See source | 2026/08/04 | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265578See source | 2026/08/04 | Official source ↗ |
| Guangdong Wan Tai Ke Chuang Pharma Co., Ltd. romanized | 国药准字H20263149See source | 2026/01/20 | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H43020028See source | 2026/10/16 | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H20269253See source | 2026/10/16 | Official source ↗ |
NHSA approval numbers 30
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Shanghai Shang Yao Xin Ya Pharma Co., Ltd. romanized | 国药准字H31021503See source | — | Official source ↗ |
| Mei Luo Pharma Co., Ltd. romanized | 国药准字H21021678See source | — | Official source ↗ |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H42020871See source | — | Official source ↗ |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51023236See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022363See source | — | Official source ↗ |
| Hubei Mei Lin Pharma Co., Ltd. romanized | 国药准字H14020379See source | — | Official source ↗ |
| Shanxi Shuang Yan Pharma Co., Ltd. romanized | 国药准字H14020729See source | — | Official source ↗ |
| Ha Yao Group Pharmaceutical Factory romanized | 国药准字H23021442See source | — | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H43020028See source | — | Official source ↗ |
| Guangxi Wu Zhou Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H45021339See source | — | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | 国药准字H36021156See source | — | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265578See source | — | Official source ↗ |
| Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. romanized | 国药准字H20263854See source | — | Official source ↗ |
| Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized | 国药准字H20263149See source | — | Official source ↗ |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H42020871See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022363See source | — | Official source ↗ |
| Hubei Mei Lin Pharma Co., Ltd. romanized | 国药准字H14020379See source | — | Official source ↗ |
| Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H34023638See source | — | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | 国药准字H36021156See source | — | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265578See source | — | Official source ↗ |
| Guangdong Wan Tai Yuan Ke Chuang Pharma Co., Ltd. romanized | 国药准字H20263149See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022363See source | — | Official source ↗ |
| Mei Luo Pharma Co., Ltd. romanized | 国药准字H21021679See source | — | Official source ↗ |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H42020872See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022364See source | — | Official source ↗ |
| Shanxi Shuang Yan Pharma Co., Ltd. romanized | 国药准字H14022626See source | — | Official source ↗ |
| Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H34023637See source | — | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H43020027See source | — | Official source ↗ |
| Guangxi Wu Zhou Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H45021338See source | — | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | 国药准字H36021155See source | — | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265577See source | — | Official source ↗ |
| Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. romanized | 国药准字H20263855See source | — | Official source ↗ |
| Wuhan Jiu An Pharma Co., Ltd. romanized | 国药准字H42020872See source | — | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H43020027See source | — | Official source ↗ |
| Hainan Guang Sheng Yu Pharmaceutical Co., Ltd. romanized | 国药准字H20265577See source | — | Official source ↗ |
| Mei Luo Pharma Co., Ltd. romanized | 国药准字H21021678See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022364See source | — | Official source ↗ |
| Guo Yao Group Guo Rui Pharma Co., Ltd. romanized | 国药准字H34023638See source | — | Official source ↗ |
| Hunan Ke Lun Pharmaceutical Co., Ltd. romanized | 国药准字H43020028See source | — | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | 国药准字H36021155See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022364See source | — | Official source ↗ |
| Mei Luo Pharma Co., Ltd. romanized | 国药准字H21021679See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022364See source | — | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | 国药准字H61022363See source | — | Official source ↗ |
| Chengdu Di Yi Pharmaceutical Co., Ltd. romanized | 国药准字H51023235See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053846See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053846See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053847See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053847See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053846See source | — | Official source ↗ |
| Rui Yang Pharmaceutical Co., Ltd. romanized | 国药准字H20053847See source | — | Official source ↗ |
| Xian Di Sai Bio Pharma Co., Ltd. romanized | 国药准字H61021775See source | — | Official source ↗ |
| Guangdong Yue He Ze Drug Research Co., Ltd. romanized | 国药准字H20265708See source | — | Official source ↗ |
Under review 13
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Suzhou Erye Pharmaceutical Co., Ltd | CYHS2504472 | 2025/12/30 | Official source ↗ |
| Suzhou Erye Pharmaceutical Co., Ltd | CYHS2504471 | 2025/12/30 | Official source ↗ |
| Guangdong Da Xiang Pharmaceutical Co., Ltd. romanized; Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | CYHS2601857 | 2026/08/03 | Official source ↗ |
| Suzhou Lang Ke Bio Technology Co., Ltd. romanized; Jiangsu Hai An Pharma Co., Ltd. romanized | CYHS2502490 | 2025/07/12 | Official source ↗ |
| Suzhou Lang Ke Bio Technology Co., Ltd. romanized; Jiangsu Hai An Pharma Co., Ltd. romanized | CYHS2502489 | 2025/07/12 | Official source ↗ |
| Hai Tao Xin Yao Research and Development (Jiangsu) Co., Ltd. romanized; Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | CYHS2500734 | 2025/02/13 | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | CYHB2650137 | 2026/06/16 | Official source ↗ |
| Jiangxi Gan Nan Hai Xin Pharma Co., Ltd. romanized | CYHB2650136 | 2026/06/16 | Official source ↗ |
| HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CYHS2600795 | 2026/04/08 | Official source ↗ |
| HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CYHS2600794 | 2026/04/08 | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | CYHS2503278 | 2025/09/05 | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | CYHS2503277 | 2025/09/05 | Official source ↗ |
| Hainan Yun Ding Pharmaceuticals Technology Co., Ltd. romanized; Haikou Qi Li Pharmaceutical Co., Ltd. romanized | CYHS2502675 | 2025/07/24 | Official source ↗ |
Generic-filing companies this year 2
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Guangdong Da Xiang Pharmaceutical Co., Ltd. romanized; Hainan Tong Yong San Yang Pharma Co., Ltd. romanized | CYHS2601857 | 2026/08/03 | Official source ↗ |
| HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CYHS2600795 | 2026/04/08 | Official source ↗ |
| HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CYHS2600794 | 2026/04/08 | Official source ↗ |
API companies with A status 4
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd. romanized | Y20230001264 | 2025/10/23 | Official source ↗ |
| Xian Li Jun Pharmaceutical Co., Ltd. romanized | Y20190005670 | 2026/01/07 | Official source ↗ |
| Huang Shi Huang Kang Pharma Co., Ltd. romanized | Y20190004886 | — | Official source ↗ |
| Mei Luo Pharma Co., Ltd. romanized | Y20190004202 | 2025/01/16 | Official source ↗ |
Trial registrations 2025/2026 —
Not loaded
Sources and dates
- FDA Orange Book
- 2026/11/06
- CDE acceptance and review
- 2026/11/13 06:42
- Chemical Drug Catalog
- 2026/11/13 06:39
- API registration records
- 2026/11/13 06:41
- NHSA drug code database
- 2026/10/23
- Trial registry
- 2026/11/13 08:09 · Incomplete coverage
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Formulation crosswalk to INJECTABLE / INJECTION, based on the Chinese Pharmacopoeia general formulation provisions, rule CHP-FORM-088. Chinese Pharmacopoeia general chapter 0102
Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗
Name and dosage-form matching sources
- NMPA reference-product directory, Shaanxi MPA republication ↗ · 26-188 · 2019/06/04
- Chinese Pharmacopoeia 2025, formulation chapter; site crosswalk ↗ · See source
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy